Programme - Universität Bielefeld

Wednesday, August 23rd, 2023

12:30 – 13:00

Registration

13:00 – 13:15

Opening Ceremony and Welcome address

Prof. Dr. Harald Kolmar

13:15 – 14:00	Towards next generation drug payloads and linkers Prof. Dr. Edward Tate Imperial College London
14:00 – 14:15	Ex Vivo Mass Spectrometry-Based Biodistribution Analysis of an Immune-Stimulating Antibody Conjugate Bearing a Protease-Cleavable and Acid-Labile Linker Lydia Bisbal Lopez Università degli Studi di Milano
14:15 – 14:30	Small Molecule-Drug Conjugates directed against Fibroblast Activation Protein Aureliano Zana Philochem
14:30 – 15:00	Coffee Break

15:00 – 15:45	All-on-resin synthetic strategies for linker-payload conjugates Prof. Dr. Daniel Garcia Rivera University of Havana
15:45 – 16:00	In vivo evaluation of Amanitin-based Fc-small molecule drug conjugates for PSMA-targeted prostate cancer therapy Daniela Carraturo Heidelberg Pharma Research GmbH

16:00 – 16:45	New stimuli responsive self-immolative donors for unconventional payload-conjugated ADCs Prof. Dr. Maurizio Taddei University of Siena
16:45 – 17:00	Self-Purified DNA-Encoded Chemical Libraries Michelle Keller ETH Zürich
17:00 – 17:30	Affinity Enhancement of Protein Ligands by Reversible-Covalent Engagement of Lysine Residues Dr. Alberto Dal Corso Università degli Studi di Milano
20:00	Speakers Dinner

09:00 – 09:45	Shrinking the magic bullet to penetrate solid tumours Dr. Mahendra Deonarain Antikor Biopharma Ltd
09:45 – 10:15	In-silico approach for identification of ADC targets with better tumor selectivity Dr. Kishor Bhatia Lantern Pharma
10:15 – 10:45	Coffee Break

10:45 – 11:30	Targeting the αVβ6 integrin biomarker with peptide-drug conjugates: any hope for precise treatment of tumor/fibrotic diseases? Prof. Dr. Franca Zanardi University of Parma
11:30 – 12:00	Oxime-linked peptide-anthracycline conjugates as good tools in the research of targeted tumor therapy Prof. Dr. Gábor Mezõ Eötvös Loránd University
12:00 – 13:30	Lunch

13:30 – 14:15	Tackling the tumor microenvironment with bioconjugates and near infrared probes Prof. Dr. Andreas Tzakos University of Ioannina
14:15 – 14:45	Peptide-based targeting of brain tumours Prof. Dr. Pirjo Laakkonen University of Helsinki
14:45 – 15:00	Pre-Clinical Testing of Newly Developed Targeted Therapeutics Balázs Vári National Institute of Oncology, HU
15:00 – 15:30	Coffee Break

15:30 – 16:15

Embracing tumor complexity for next generation ADCs: a case study to target the TME with TLR-ADC

Dr. Jean Wakim Merck

16:15 – 16:30

Bombesin-based Peptide Drug Conjugates for Targeted Tumour Therapy

Jacopo Gomena Eötvös Loránd University

16:30 – 17:00

Glioma targeting peptide-drug conjugates with in vivo activity

Dr. Ivan Randelovic Kineto Lab

17:00 – 18:00	Poster Session
20:00	Conference Dinner

09:00 – 09:45	Pseudo-natural peptides and neobiologics Prof. Dr. Hiroaki Suga The University of Tokyo
09:45 – 10:15	Peptide-Drug Conjugates for Tumor Targeting Prof. Dr. Norbert Sewald Bielefeld University
10:15 – 10:45	Tuning Selectivity and Efficacy in isoDGR-based Small Molecule-Drug Conjugates for Tumor Targeting Dr. Silvia Gazzola University of Insubria
10:45 – 11:15	Towards the design and biological activity of cell-permeable peptide-drug conjugates Prof. Dr. Ines Neundorf University of Cologne
11:15 – 11:45	Coffee Break

11:45 – 12:30	SMDCs and ADCs with Tailored Payload-Linker Designs for the Treatment of Solid Tumors and Hematological Malignancies Dr. Hans-Georg Lerchen Vincerx Pharma GmbH
12:30 – 13:00	From Dextraknobs to Dextramabs: Applications of a novel ADC format Prof. Dr. Harald Kolmar Technical University of Darmstadt
13:00 – 13:45	From encoded libraries to targeted therapeutics Prof. Dr. Dario Neri Philogen & ETH Zürich
13:45 – 14:00	Closing Remarks Prof. Dr. Norbert Sewald & Prof. Dr. Harald Kolmar